Table 2.
Patient and Tumor Characteristics.
| Characteristic | Values | Protocol Eligible N=219* | Evaluable for patient-reported outcomes N=139 | Evaluable for physician-reported outcomes N=150 |
|---|---|---|---|---|
| Age, years | Mean | 64.7 | 63.4 | 63.1 |
| Range | 27-87 | 27-87 | 27-87 | |
| Gender, n (%) | Female | 108 (49.3) | 56 (40.3) | 62 (41.3) |
| Male | 111 (50.7) | 83 (59.7) | 88 (58.7) | |
| Race, n (%) | White | 206 (94.1) | 130 (93.5) | 138 (92.0) |
| Black | 8 (3.7) | 5 (3.6) | 7 (4.7) | |
| Other, unknown | 5 (2.3) | 4 (2.9) | 5 (3.3) | |
| Performance status, n (%) | ECOG 0 | 143 (65.3) | 93 (66.9) | 98 (65.3) |
| ECOG 1 | 76 (34.7) | 46 (33.1) | 52 (34.7) | |
| WHO tumor grade, n (%) | High | 32 (14.6) | 14 (10.1) | 16 (10.7) |
| Low | 187 (85.4) | 125 (89.9) | 134 (89.3) | |
| Tumor Type, n (%) | Adenocarcinoma NOS | 200 (91.3) | 131 (94.2) | 141 (94.0) |
| Mucinous Carcinoma | 12 (5.5) | 4 (2.9) | 5 (3.3) | |
| Other | 7 (3.2) | 4 (2.9) | 4 (2.7) | |
| Lymphatic invasion, n (%) | Absent | 201 (91.8) | 129 (92.8) | 140 (93.3) |
| Present | 18 (8.2) | 10 (7.2) | 10 (6.7) | |
| Vascular invasion, n (%) | Absent | 204 (93.2) | 130 (93.5) | 140 (93.3) |
| Present | 15 (6.8) | 9 (6.5) | 10 (6.7) | |
| Tumor Location, n (%) | Left-sided | 67 (30.6) | 53 (38.1) | 56 (37.3) |
| Right-sided | 132 (60.3) | 74 (53.2) | 79 (52.7) | |
| Transverse colon | 20 (9.1) | 12 (8.6) | 15 (10.0) | |
| Tumor size | Mean | 5.1 | 4.9 | 4.8 |
| Range | 1-25 | 1-25 | 1-25 | |
| Number of lymph nodes examined | Mean | 22.0 | 21.5 | 22.4 |
| Range | 3-134 | 3-119 | 3-134 | |
*
Includes 51 patents with MMR-D tumors which were not part of the analyses included in this report
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NOS, not otherwise specified; WHO, World Health Organization.